3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$710,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7506 (117th), H.R. 5376 (117th), H.Res. 1330 (117th), H.R. 5801 (117th)

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (117th)

Budget/Appropriations BUD

Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 8295 (117th), H.R. 8239 (117th), S. 4659 (117th), S. 4661 (117th)

Medical/Disease Research/Clinical Labs MED

Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."

LobbyistCovered position, as disclosed
KWAMME ANDERSON —
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 4348 (117th), H.R. 7667 (117th), H.R. 6833 (117th), S. 3799 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.